Why take this detour?

An easier entrance

Route 66 Peptides is a personal publication about published research. A road name suits my curiosity about where molecules can travel, and what has to change to let them through. The oral secretagogue experiments in dogs offer a particularly absorbing example: the route improves through chemical redesign.

I admire a practical improvement more when its awkward consequences remain visible. The NN703 characterization gives that preference something concrete to work on, with oral absorption in dogs beside a separate cortisol observation.

Convenience has an appeal of its own. Inventiveness alone seems worthy of a close look, even when a candidate never reaches treatment. The harder question is what to carry forward from that achievement: a design principle, a useful experimental tool, or eventually a medicine. Each possibility seems worth understanding on its own terms.

The trial of intravenous ipamorelin after bowel surgery gives the parent peptide a separate clinical test. Its missed primary endpoint is an awkward destination alongside the oral-design achievements in animals. I feel little urge to rescue the ending. These are different compounds, routes and questions; there is room for admiration of an engineering result and disappointment with a clinical one.

Editorial remit

The name is an editorial title. Route 66 Peptides is not a business, a local practice or a source of treatment. There is no shop behind the notebook.

An experiment can sustain an argument all afternoon. A person's health asks for an assessment that these pages cannot provide. Nothing on these pages is medical advice. Personal decisions about medicines require a qualified health professional who can assess the person involved.

The contact page explains the current correspondence arrangements and the information needed to identify a possible correction.